antipyrine has been researched along with Fibrosis in 2 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to examine the effect of edaravone, a free radical scavenger, on the development of fibrosis and autoimmunity in two different mouse models of SSc." | 7.77 | The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. ( Asano, Y; Iwata, Y; Kadono, T; Ogawa, A; Ogawa, F; Sato, S; Shimizu, K; Takenaka, M; Yanaba, K; Yoshizaki, A, 2011) |
| " The aim of this study was to examine the effect of edaravone, a free radical scavenger, on the development of fibrosis and autoimmunity in two different mouse models of SSc." | 3.77 | The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. ( Asano, Y; Iwata, Y; Kadono, T; Ogawa, A; Ogawa, F; Sato, S; Shimizu, K; Takenaka, M; Yanaba, K; Yoshizaki, A, 2011) |
| "Antipyrine clearance was positively correlated with serum albumin (r2 = 0." | 2.69 | Antipyrine clearance in chronic and neoplastic liver diseases: a study of 518 patients. ( Castellano, R; Di Rocco, P; Gasbarrini, G; Grieco, A; Marcoccia, S; Matera, A; Ragazzoni, E; Vecchio, FM, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yoshizaki, A | 1 |
| Yanaba, K | 1 |
| Ogawa, A | 1 |
| Iwata, Y | 1 |
| Ogawa, F | 1 |
| Takenaka, M | 1 |
| Shimizu, K | 1 |
| Asano, Y | 1 |
| Kadono, T | 1 |
| Sato, S | 1 |
| Grieco, A | 1 |
| Castellano, R | 1 |
| Matera, A | 1 |
| Marcoccia, S | 1 |
| Di Rocco, P | 1 |
| Ragazzoni, E | 1 |
| Vecchio, FM | 1 |
| Gasbarrini, G | 1 |
1 trial available for antipyrine and Fibrosis
| Article | Year |
|---|---|
Antipyrine clearance in chronic and neoplastic liver diseases: a study of 518 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipyrine; Carcinoma, Hepatocellular; Evaluation Studie | 1998 |
1 other study available for antipyrine and Fibrosis
| Article | Year |
|---|---|
The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis.
Topics: Animals; Antipyrine; Bleomycin; Disease Models, Animal; Edaravone; Fibrosis; Free Radical Scavengers | 2011 |